TITLE

How HIV Treatment Failure Occurs Without Resistance

AUTHOR(S)
Breindl, Anette
PUB. DATE
September 2012
SOURCE
BioWorld Today;9/5/2012, Vol. 23 Issue 172, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on a mathematical model developed by scientists which may be able to help determine the best way to prevent resistance to currently available HIV drugs and identify effective combinations of new drugs early on in clinical development. According to Alison Hill of Harvard University, their model can predict the clinical significance of mutations in the context of drug combinations and different levels of patient compliance with their drug regimens.
ACCESSION #
79792667

 

Related Articles

  • A Mathematical Model for HIV Drug-Resistance. Faedo, Ivan; Raimundo, Silvia Martorano; Venturino, Ezio // AIP Conference Proceedings;9/30/2010, Vol. 1281 Issue 1, p724 

    In this paper we present a mathematical model of the transmission of HIV infection here the individuals receive antiretroviral drugs but may not respond to treatment. In such case the latter can be changed to a different therapy, and individuals may or may not respond also to this second set of...

  • Gender Inequities in Quality of Care among HIV-Positive Individuals Initiating Antiretroviral Treatment in British Columbia, Canada (2000–2010). Carter, Allison; Eun Min, Jeong; Chau, William; Lima, Viviane D.; Kestler, Mary; Pick, Neora; Money, Deborah; Montaner, Julio S G.; Hogg, Robert S.; Kaida, Angela // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Objectives: We measured gender differences in “Quality of Care” (QOC) during the first year after initiation of antiretroviral therapy and investigated factors associated with poorer QOC among women. Design: QOC was estimated using the Programmatic Compliance Score (PCS), a validated...

  • Strategies for Preventing Mucosal Cell-Associated HIV Transmission. Whaley, Kevin J.; Mayer, Kenneth H. // Journal of Infectious Diseases;Dec2014, Vol. 210 Issue suppl_3, pS674 

    Human immunodeficiency virus (HIV) may be transmitted through either cell-free virions or leukocytes harboring intracellular HIV in bodily fluids. In recent years, the early initiation of combination antiretroviral therapy leading to virological suppression has resulted in decreased HIV...

  • Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. Pattacini, Laura; Murnane, Pamela M.; Baeten, Jared M.; Fluharty, Tayler R.; Thomas, Katherine K.; Bukusi, Elizabeth; Katabira, Elly; Mugo, Nelly; Donnell, Deborah; Lingappa, Jairam R.; Celum, Connie; Marzinke, Mark; McElrath, M. Juliana; Lund, Jennifer M. // Journal of Infectious Diseases;6/15/2015, Vol. 211 Issue 12, p1943 

    Background. Antiretroviral preexposure prophylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immunodeficiency virus (HIV) prevention strategy for populations at high risk of HIV acquisition. Although the primary mode of action...

  • An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies. Martín, Verónica; Perales, Celia; Fernández-Algar, María; Dos Santos, Helena G.; Garrido, Patricia; Pernas, María; Parro, Víctor; Moreno, Miguel; García-Pérez, Javier; Alcamí, José; Torán, José Luis; Abia, David; Domingo, Esteban; Briones, Carlos // PLoS ONE;12/13/2016, Vol. 11 Issue 12, p1 

    The response of human immunodeficiency virus type 1 (HIV-1) quasispecies to antiretroviral therapy is influenced by the ensemble of mutants that composes the evolving population. Low-abundance subpopulations within HIV-1 quasispecies may determine the viral response to the administered drug...

  • Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy. Mirani, Gayatri; Williams, Paige L.; Chernoff, Miriam; Abzug, Mark J.; Levin, Myron J.; Seage III, George R.; Oleske, James M.; Purswani, Murli U.; Hazra, Rohan; Traite, Shirley; Zimmer, Bonnie; Van Dyke, Russell B. // Clinical Infectious Diseases;12/15/2015, Vol. 61 Issue 12, p1850 

    Background. Combination antiretroviral therapy (cART) has resulted in a dramatic decrease in human immunodeficiency virus (HIV)-related opportunistic infections and deaths in US youth, but both continue to occur. Methods. We estimated the incidence of complications and deaths in IMPAACT P1074, a...

  • Recent developments in the effort to cure HIV infection: going beyond N = 1. Siliciano, Janet D.; Siliciano, Robert F. // Journal of Clinical Investigation;Feb2016, Vol. 126 Issue 2, p409 

    Combination antiretroviral therapy (ART) can suppress plasma HIV to undetectable levels, allowing HIV-infected individuals who are treated early a nearly normal life span. Despite the clear ability of ART to prevent morbidity and mortality, it is not curative. Even in individuals who have full...

  • HIV-specific CD8⁺ T cells and HIV eradication. Jones, R. Brad; Walker, Bruce D. // Journal of Clinical Investigation;Feb2016, Vol. 126 Issue 2, p455 

    After the success of combination antiretroviral therapy (cART) to treat HIV infection, the next great frontier is to cure infected persons, a formidable challenge. HIV persists in a quiescent state in resting CD4+ T cells, where the replicative enzymes targeted by cART are not active. Although...

  • Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. Wagh, Kshitij; Bhattacharya, Tanmoy; Williamson, Carolyn; Robles, Alex; Bayne, Madeleine; Garrity, Jetta; Rist, Michael; Rademeyer, Cecilia; Yoon, Hyejin; Lapedes, Alan; Gao, Hongmei; Greene, Kelli; Louder, Mark K.; Kong, Rui; Karim, Salim Abdool; Burton, Dennis R.; Barouch, Dan H.; Nussenzweig, Michel C.; Mascola, John R.; Morris, Lynn // PLoS Pathogens;3/30/2016, Vol. 12 Issue 3, p1 

    The identification of a new generation of potent broadly neutralizing HIV-1 antibodies (bnAbs) has generated substantial interest in their potential use for the prevention and/or treatment of HIV-1 infection. While combinations of bnAbs targeting distinct epitopes on the viral envelope (Env)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics